Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Karolinska Development, also known as KDventures, is a publicly-listed investment organization based in Solna, Sweden. Founded in 2003, it focuses on investing in Nordic life science companies that are developing treatments for serious diseases. The organization leverages its close ties with the Karolinska Institutet and other leading Nordic universities to access cutting-edge medical innovations. This strategic positioning allows Karolinska Development to identify and support promising startups in the biotech and healthcare sectors.
The firm operates with a team of experienced professionals skilled in research, development, financing, and commercialization. This expertise is crucial for building and growing its portfolio companies. As of now, Karolinska Development manages a portfolio of 11 companies, emphasizing its commitment to the life sciences sector. The organization is publicly traded on Nasdaq Stockholm under the ticker KDEV, which provides it with a unique capital structure that differs from traditional venture capital firms.
Over the years, Karolinska Development has achieved notable milestones, including successful exits such as Forendo Pharma, acquired by Organon for USD 945 million in 2021, and Xspray, which had a successful exit in 2015. These achievements underscore the firm’s ability to generate significant returns for its stakeholders while contributing to advancements in healthcare.
Karolinska Development focuses on early-stage investments in pharmaceutical and medtech companies, particularly those progressing through phase 2 clinical trials or early commercialization phases. The firm primarily targets investments in the biotech and healthcare sectors, emphasizing companies that address serious diseases. Their investment strategy involves a syndication model, partnering with other leading investors in the life sciences sector to maximize value generation and patient benefit.
The organization typically invests at the pre-seed, seed, and Series A stages, allowing them to engage with startups at critical points in their development. Karolinska Development seeks companies that demonstrate significant potential for value creation and align with their mission of improving patient outcomes. Their focus on patient benefit ensures that investments are directed towards innovations that can lead to meaningful health advancements.
Karolinska Development's portfolio includes a diverse range of companies, each contributing to advancements in the life sciences sector. Notable companies in their portfolio include:
This portfolio reflects Karolinska Development's commitment to supporting innovative solutions in the life sciences, particularly those that address serious health challenges.
Viktor Drvota: Chief Executive Officer. Viktor has extensive experience in life sciences investments and has been instrumental in leading Karolinska Development since its inception.
Johan Dighed: Chief Legal Officer and Deputy CEO. Johan oversees legal matters and compliance, ensuring that the organization adheres to regulatory standards.
Hans Christopher "HC" Toll: Chief Financial Officer. HC manages the financial operations of the firm, bringing a wealth of experience in financial management within the life sciences sector.
John Öhd: Chief Scientific Officer/Venture Partner. John provides scientific expertise and guidance, helping to evaluate the technical aspects of potential investments.
Elisabet Gimbringer: Financial Manager. Elisabet is responsible for financial reporting and analysis, contributing to the firm's strategic financial planning.
Eva Montgomerie: Head of Accounting. Eva manages the accounting functions, ensuring accurate financial records and compliance with accounting standards.
Mathias Frenzel: Investment Analyst. Mathias conducts market research and analysis to support investment decisions, focusing on emerging trends in the life sciences sector.
To pitch Karolinska Development, founders should use the official website's contact form. It is essential to include a comprehensive pitch deck that outlines the startup's vision, technology, market potential, and team qualifications. The firm prefers detailed information that demonstrates the startup's alignment with their investment focus on serious diseases.
Response times can vary, but founders should expect a thorough review process. Warm introductions through mutual connections in the life sciences sector can enhance the chances of a successful pitch.
In June 2025, Karolinska Development announced a SEK 158 million raise for OssDsign, a company focused on orthobiologics. This funding will support the company's growth and development initiatives.
In August 2025, Modus Therapeutics raised SEK 28.3 million in an oversubscribed unit issue to fund the development of sevuparin for chronic kidney disease with anemia.
In November 2025, BOOST Pharma successfully raised SEK 34 million via a directed share issue to Sound Bioventures, furthering its stem cell therapy initiatives.
In February 2026, SVF Vaccines entered into a reverse acquisition agreement with Novakand Pharma, valued at approximately SEK 55 million, marking a significant milestone for the company.
Additionally, Umecrine Cognition appointed a new CEO in April 2025, signaling a strategic shift in leadership as the company continues to focus on Parkinson's disease.
What are Karolinska Development's investment criteria?
Karolinska Development invests in early-stage pharmaceutical and medtech companies, particularly those in phase 2 clinical trials or early commercialization phases. They focus on serious diseases and seek companies with significant potential for value generation.
How can I pitch to Karolinska Development?
Founders can pitch their startups through the official website. It is advisable to include detailed information about the company's technology, market potential, and team in the pitch deck.
What makes Karolinska Development different from other investors?
Karolinska Development is unique due to its close ties with the Karolinska Institutet and other leading Nordic universities, providing access to cutting-edge medical innovations. Additionally, they employ a syndication model, partnering with other investors to enhance value generation.
What is the geographic focus of Karolinska Development?
The firm primarily invests in Nordic countries, with a strong emphasis on Sweden. Their focus is on life sciences companies that are developing treatments for serious diseases.
What is the typical check size for investments?
While specific check sizes are not disclosed, Karolinska Development typically invests at the pre-seed, seed, and Series A stages, indicating a range that aligns with early-stage funding needs.
What kind of support does Karolinska Development provide to portfolio companies?
Karolinska Development adds value through strategic guidance, access to funding, and partnerships with other institutional investors, enhancing the growth potential of its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.